Bergen, Norway 31 January 2022
The overall aim for Lifecare in 2022 is to initiate clinical activities in linewith our development milestones. The planned activities will bring our uniqueSencell osmotic sensing technology a significant step closer to regulatoryapproval as a medical device for diabetes care. Preparations to ensure aregulatory approved platform have been initiated and we are strengthening theteam in Germany at Lifecare NanoBioSensors with supplementary expertise innano-microfabrication techniques and project control.
Read more in the Lifecare January newsletter:https://lifecare.no/news/information-from-lifecare-january-2022/
This is LifecareLifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).
Further information Joacim Holter, CEO, Lifecare AS, email@example.com,+47 40 05 90 40
This stock exchange announcement was published by Kine Hereid, InvestorRelations at Lifecare AS, on 31.01.22 at 10:10 CET.